XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Total revenues $ 7,051 $ 7,042 $ 20,002 $ 19,892
Costs and expenses:        
Cost of goods sold 1,565 1,395 4,408 4,261
Research and development expenses 1,457 1,149 4,310 3,429
Acquired in-process research and development expenses 91 448 808 786
In-process research and development impairment 0 0 0 2,700
Selling, general and administrative expenses 1,315 1,213 4,482 3,653
Total costs and expenses 4,428 4,205 14,009 14,829
Operating income 2,623 2,837 5,993 5,063
Interest expense (232) (229) (692) (709)
Other income (expense), net (72) (176) (95) (571)
Income before income taxes 2,318 2,432 5,206 3,783
Income tax expense (146) (646) (1,010) (850)
Net income 2,172 1,786 4,196 2,933
Net loss attributable to noncontrolling interest 8 3 40 19
Net income attributable to Gilead $ 2,180 $ 1,789 $ 4,236 $ 2,952
Basic earnings per share attributable to Gilead (in dollars per share) $ 1.75 $ 1.43 $ 3.39 $ 2.35
Shares used in basic earnings per share attributable to Gilead calculation (in shares) 1,248 1,255 1,249 1,255
Diluted earnings per share attributable to Gilead (in dollars per share) $ 1.73 $ 1.42 $ 3.37 $ 2.34
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) 1,257 1,261 1,259 1,261
Product sales        
Revenues:        
Total revenues $ 6,994 $ 6,978 $ 19,864 $ 19,650
Royalty, contract and other revenues        
Revenues:        
Total revenues $ 56 $ 64 $ 138 $ 242